Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on July 3, 2015. The filing discloses the entry into a material definitive agreement involving a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company closed a securities purchase agreement with four investors on July 3, 2015. The transaction generated aggregate proceeds of $450,000.
- Securities Issued: 180,000 shares of Series A Preferred Stock and warrants to purchase 36,000 shares of common stock.
- Purchase Price: $2.50 per share of Series A Preferred Stock.
- Warrant Terms: Exercise price of $5.00 per share; five-year term.
- Dividends: Holders of Series A Preferred Stock are not entitled to receive dividends.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity ratios outside of the specific transaction proceeds.
Material Changes and Conversion Mechanics
The Series A Preferred Stock includes specific conversion rights tied to future financing or acquisition events:
- Conversion Price: The lower of (i) the price per share of an Acquisition or a Next Equity Financing (minimum $1,000,000) closed before October 1, 2015, or (ii) $2.50 if the price is higher or if no such event occurs by October 1, 2015.
- Automatic Conversion: Shares automatically convert to common stock immediately prior to an Acquisition or Next Equity Financing (if closed before October 1, 2015) or on October 1, 2015.
Guidance, Risks, and Unusual Items
Registration Rights: Investors have the right to request inclusion of the underlying common stock and warrants in any future SEC registration statement filed by the Company.
Regulatory Exemption: The securities were issued pursuant to Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. Investors represented they are accredited investors acquiring the securities for investment purposes only.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding operational performance or future financial projections.
Investor Verification Checklist
- Verify the full text of the Certificate of Designation (Exhibit 3.1) and the Securities Purchase Agreement (Exhibit 10.1) for complete terms.
- Confirm the identity of the four investors and their accreditation status.
- Monitor the Company's capitalization table for the dilution impact of the 180,000 preferred shares and 36,000 warrant shares upon conversion or exercise.
- Track the October 1, 2015 deadline for the automatic conversion trigger or the requirement for a $1,000,000+ equity financing.